Hybrid Biotherapeutics Revenue

About Hybrid Biotherapeutics

Hybrid Bio is an early-stage biotech company that was created by a group of scientists and industry executives to develop a novel cell therapy approach in oncology. Our technology, that have originated in the University of Pennsylvania, is a revolutionary novel type of autologous combinational cell therapy enhancing efficacy of therapeutic antibodies in solid and liquid tumors. It is based on newly discovered Hybrid neutrophils possessing unique composite features of cytotoxic and antigen-presenting cells (APCs). Hybrid Neutrophils not only kill antibody-opsonized tumor cells with similar efficacy as NK cells, but also possess the ability to uptake tumor antigens and efficiently cross present them to CD8+ T-cells generating strong tumor-specific immune response in the patient. We have determined the mechanism of action and developed a process that allows origination of Hybrid Neutrophils from peripheral blood, requires no gene modification, is suitable for repetitive dosing in combination with antibodies, and uses only FDA-approved materials. Our technology can expand therapeutic window for multiple registered antibodies allowing their effective use in various solid and hematological tumors that are currently completely, or mostly resistant to antibody therapy, including such indications as lung cancer (NSCLC), breast cancer and many others. We believe that our technology has the potential of giving thousands of patients an opportunity not only to eliminate their tumors but also to prevent recurrence of the disease.

View contact profiles from Hybrid Biotherapeutics